PCSK9 and atherosclerosis: However, analyses of the statin, PCSK9 mAb, and ezetimibe cardiovascular outcomes trials reveal subgroups of patients at very high or extremely high ASCVD risk with lower LDL-C levels for whom further LDL-C lowering may have similar cost-effectiveness as in lower risk patients with higher LDL-C levels [35].